

MEDIA CONTACT:

Amanda Orloske
Marketing Manager, Unigen
Phone: 360.486.7441

Email: AOrloske@Unigen.net



UnivestIn® Reproductive Toxicity Studies Published

Continued research on UnivestIn® goes beyond the norm for dietary supplements, and comes out looking good in three reproductive toxicity studies.

Seattle, WA – August 27, 2015: Unigen continues to add to the extensive body of research surrounding UnivestIn®, their innovative joint health ingredient, with new studies on the effects of the compound on reproduction in rats. Unigen performed 3 separate but related studies, labeled as Part-I through III. Each part addresses a different aspect of fertility, reproduction and development.

- Part-I: Effect of treatment at a stage of embryo to fetus development
- Part-II: Effect of treatment at the time of pregnancy (gestation) and the newborns (their development, behavior and sexual function)
- Part-III: Effect of treatment on maternal fertility and early embryonic development

Recently all three parts have been published in the Birth Defects Research Journal, Part B. The completion and publication of these studies adds to the robust safety package Unigen has been compiling on UnivestIn for over 10 years. All three studies showed no adverse effects on reproduction up to 1,000mg/kg dosing.

When asked about the research, Unigen’s CEO, Regan Miles answered, “Our commitment to continued research on UnivestIn, and all of our ingredients, is a big priority for Unigen. The publication of these studies furthers an already extensive safety profile we have been building.”

Abstracts for the publications can be found at the following links and more information on UnivestIn can be found at www.UnivestIn.com:

Part-I: <http://onlinelibrary.wiley.com/doi/10.1002/bdrb.21150/abstract>

Part-II: <http://onlinelibrary.wiley.com/doi/10.1002/bdrb.21142/abstract>

Part-III: <http://onlinelibrary.wiley.com/doi/10.1002/bdrb.21143/abstract>

###

About Unigen

Unigen discovers, develops and manufactures proprietary natural-product active ingredients for dietary supplements, functional foods, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its proprietary ingredients through our high throughput screening PhytoLogix™ approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety and efficacy are documented with extensive preclinical *in vitro* and *in vivo* testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories, and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution and marketing of end-products in each of Unigen's target markets.